One Dose, Two Years: New Cholesterol Therapy Shows Long-Lasting Results
A Two-Year Shield Against Bad Cholesterol
Scribe Therapeutics revealed preclinical data for STX-1150 and STX-1200 at the American Heart Association Scientific Sessions in Chicago. The company reported that a single injection of STX-1150 suppressed LDL cholesterol in non-human primates for at least two years. This duration far exceeds the typical monthly or quarterly dosing schedules of current cholesterol drugs. The data marks a significant step toward reducing patient burden in cardiovascular care.
The study focused on non-human primates as a close biological model for humans. Researchers administered a single dose of STX-1150 and tracked lipid levels over time. Results showed LDL cholesterol remained at target levels throughout the two-year observation window. This suggests the therapy binds to a target that resists natural clearance. The mechanism likely involves a long-acting molecular switch that stays active for an extended period.
Why One Dose Could Change Treatment Adherence
Current statin and PCSK9 inhibitor regimens require frequent dosing, which often leads to missed doses. A single annual or biennial shot removes the need for constant medication management. This approach could dramatically improve adherence rates among patients. Scribe Therapeutics plans to expand testing in larger primate cohorts. The company aims to validate the two-year efficacy claim before moving to human trials.
How long did one dose of STX-1150 control cholesterol? Preclinical data indicates a single injection maintained LDL cholesterol at target levels for at least two years in non-human primates. This duration is unprecedented for lipid-lowering therapies.
Frequently Asked Questions
What is the mechanism behind the long duration? The therapy likely targets a protein that remains bound for an extended period, resisting natural breakdown. This sustained activity explains why one dose lasts so long.
When will human trials begin? Scribe Therapeutics is expanding primate studies to confirm the two-year efficacy. Human clinical trials are planned following successful preclinical validation.